Vanda Pharmaceuticals Inc
NASDAQ:VNDA
Vanda Pharmaceuticals Inc
NASDAQ:VNDA
Price:
4.82 USD
4.33%
Market Closed
Updated:
Apr 30, 2024
Vanda Pharmaceuticals Inc
Cash from Operating Activities
|
Vanda Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Vanda Pharmaceuticals Inc
NASDAQ:VNDA
|
Cash from Operating Activities
$12.8m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
See Also
What is Vanda Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
12.8m
USD
12.8m
USD
Based on the financial report for Dec 31, 2023, Vanda Pharmaceuticals Inc's Cash from Operating Activities amounts to 12.8m USD.
What is Vanda Pharmaceuticals Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-16%
-16%
Over the last year, the Cash from Operating Activities growth was -60%. The average annual Cash from Operating Activities growth rates for Vanda Pharmaceuticals Inc have been -37% over the past three years , -16% over the past five years .
You don't have any saved screeners yet
